Centric Health

centrichealth.ie

Founded in 2003, Centric Health provides Primary Healthcare GP and Dental Services, Urgent Care, Radiology, Retinal Screening and Occupational Health Services to over 200,000 patients throughout Ireland and the UK each year: Centric Health GP: GP Care is delivered throughout Ireland via an expanding network of purpose-built Primary Care facilities where Centric GP Doctors, Dentists and Nurses work in tandem with Medical Specialists and HSE Primary Care teams (www.centricgp.ie). VHI Swiftcare: In response to long wait times in A & E Hospital departments, Centric Health and VHI formed the VHI Swiftcare Urgent Care network, providing non-life threatening medical care to over 1000 patients a day, 8am to 10pm, 365 days a year.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

ABSCI OPENS DOOR TO NEW BIOTECHNOLOGY CAMPUS

Absci | October 23, 2021

news image

Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. “Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have fol...

Read More

MEDICAL

NOVAVAX SUBMITS REQUEST TO THE U.S. FDA FOR EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE

Novavax, Inc. | January 31, 2022

news image

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2. The request for EUA is based on the totality of pre-clinical, clinical and...

Read More

PALO ALTO-BASED BIOTECH STARTUP TO MASS MANUFACTURE CLINICAL-GRADE IPSCS FOR CELL THERAPY

I Peace, Inc. | July 16, 2020

news image

I Peace, Inc. (CEO: Koji Tanabe, https://ipeace.com/), a Palo Alto-based biotech startup focusing on Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs) has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-size closed cassette. The system was developed in collaboration with FANUC CORPORATION (Head Office: Oshino, Yamanashi Prefecture, Japan; CEO: Kenji Yamaguchi). The technology is modular and scalable with a small foot...

Read More

CELL AND GENE THERAPY

ELEVATEBIO ANNOUNCES ISSUANCE OF U.S. PATENT PROVIDING PROTECTION FOR RNA-GUIDED NUCLEASES IDENTIFIED THROUGH ITS LIFE EDIT GENE EDITING PLATFORM

ElevateBio | November 25, 2021

news image

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...

Read More
news image

MEDICAL

ABSCI OPENS DOOR TO NEW BIOTECHNOLOGY CAMPUS

Absci | October 23, 2021

Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. “Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have fol...

Read More
news image

MEDICAL

NOVAVAX SUBMITS REQUEST TO THE U.S. FDA FOR EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE

Novavax, Inc. | January 31, 2022

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2. The request for EUA is based on the totality of pre-clinical, clinical and...

Read More
news image

PALO ALTO-BASED BIOTECH STARTUP TO MASS MANUFACTURE CLINICAL-GRADE IPSCS FOR CELL THERAPY

I Peace, Inc. | July 16, 2020

I Peace, Inc. (CEO: Koji Tanabe, https://ipeace.com/), a Palo Alto-based biotech startup focusing on Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs) has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-size closed cassette. The system was developed in collaboration with FANUC CORPORATION (Head Office: Oshino, Yamanashi Prefecture, Japan; CEO: Kenji Yamaguchi). The technology is modular and scalable with a small foot...

Read More
news image

CELL AND GENE THERAPY

ELEVATEBIO ANNOUNCES ISSUANCE OF U.S. PATENT PROVIDING PROTECTION FOR RNA-GUIDED NUCLEASES IDENTIFIED THROUGH ITS LIFE EDIT GENE EDITING PLATFORM

ElevateBio | November 25, 2021

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us